



Public Health
England

Protecting and improving the nation's health

Preview of 2nd Atlas of Variation in Liver Disease & PHE Action on Liver Disease

Thank you for joining the webinar. The session will start at 2pm. Please ensure you are on **mute**.

Please note that the webinar is being recorded.

Professor Julia Verne, Lead for Liver Disease, PHE



Public Health
England

The webinar team



Julia Verne



Liz Rolfe



Tanya
Khara-Butler



Nicola Bowtell



Kerry
Archer-Dutton

Questions can be asked by the Instant Messaging tool or by emailing neolcin@phe.gov.uk. We will pause to answer the questions throughout the webinar.

This webinar is being recorded and we are planning to make this available as a resource.



Why care about Liver Disease

- Young
 - 90% deaths < 70 years, third highest cause working age mortality, 40% deaths in 40 year olds
- Deprived and marginalised populations (BAME)
- ~90% preventable
- Deaths: unexpected, frightening, dramatic
- NCEPOD: Potentially preventable
- Little End of Life Care (except Primary Liver Cell Cancer)




A key issue for population health

In the *Annual Report of the Chief Medical Officer (CMO), Volume 1, 2011*, liver disease one of three issues for population health because:

“the only major cause of mortality and morbidity which is on the increase in England...”


In 2010, it killed more people than were killed in transport accidents and more women than cancer of the cervix.

FIGURE I.3: TREND IN MORTALITY FROM LIVER DISEASE IN RELATION TO TRENDS IN MORTALITY FROM OTHER CAUSES, ENGLAND, 1971–2007





Premature mortality from chronic liver disease and cirrhosis in people aged under 65 in the UK and European Union (EU) countries before and after 2004, and France and Sweden, 1970-2014




Preliminary
analysis

Source: European health for all database (HFA-DB) WHO/Europe July 2016)

A public health approach to Liver Cancer

Opportunities for intervention and the effectiveness of intervention diminish with progression of liver disease, whereas the relative costs of the interventions that can be applied increase

FIGURE I.5: THE POTENTIAL FOR, AND COST OF, INTERVENTION IN RELATION TO THE COURSE OF LIVER DISEASE



24 <http://data.euro.who.int/dmdb/>



- Intelligence on Liver Disease: Inequalities and Geographical Variation
 - Introduction to inequalities in liver disease
 - Local Authority Liver Disease Profiles
 - Atlases of Variation in Liver Disease (Preview the 2nd Atlas)
- Obesity
- Alcohol
- Hepatitis B & C
- Healthcare issues



Public Health
England

Intelligence on Liver Disease

Audiences:

Hepatologists

Providers (Trusts, Primary Care, Local Authorities, NGOs)

Commissioners (CCGs, STPs, Specialist Commissioning)

Government Departments

Patients, the Public, NGOs

Products:

Local Authority Liver Disease Profiles

Update of Atlas of Variation in Liver Disease

Ad-hoc reports and requests



Public Health
England

Protecting and improving the nation's health



<http://fingertips.phe.org.uk/profile/liver-disease>



Public Health
England

Protecting and improving the nation's health


Inequalities

Location, location

Variation, variation.....




Rate of years of life lost in people aged under 75 years due to mortality from chronic liver disease including cirrhosis per 100,000 population by LTLA 2012-14 in relation to the index of multiple deprivation (IMD) 2015 (1 = The least deprived; 100= The most deprived)




Source: NHS Digital Indicator Portal & Department of communities and local government



Distribution by quintile of income deprivation of deaths with an underlying cause of liver disease, 2003 to 2012, England (Source: ONS)




Age at death by deprivation quintile – all liver disease



MAP M1u65: Rate of years of life lost in people aged under 65 years due to mortality from chronic liver disease including cirrhosis per population by CCG

Standardised Years of Life Lost per 10,000, 2013-2015





Public Health
England

Protecting and improving the nation's health



<http://fingertips.phe.org.uk/profile/liver-disease>




Local Authority Liver Disease Profiles



Introduction

Death rates from liver disease are increasing in England. This is in contrast to most EU countries where liver disease death rates are falling. Between 2001 and 2012 the number of people who died with an underlying cause of liver disease in England rose from 7,641 to 10,948. This represents a 43% increase in liver deaths during this period and is in contrast to other main causes of disease which have been declining (Figure 1). Liver disease is largely preventable. Whilst approximately 5% of liver disease is attributable to autoimmune disorders (diseases characterised by abnormal functioning of the immune system), most liver disease is due to three main risk factors: alcohol, obesity and viral hepatitis.

Figure 1 - Percentage change in mortality rates, England 1990 - 2012



Key messages for Blackpool

In Blackpool, between 2010 and 2012, the average number of years of life lost¹ in people aged under 75 from liver disease is 80 per 10,000 persons. This compares to 31 for breast cancer, 32 for stroke, and 6 for road traffic accidents.

In Blackpool the rate of premature mortality from liver disease between 2010 and 2012, is significantly higher than the England average for males and significantly higher than the England average for females.

Between 2001-03 and 2010-12, the average number of people per year who died with an underlying cause of liver disease in Blackpool, increased from 88 to 94.

The rate of alcohol specific hospital admissions in 2012/13 in Blackpool is significantly higher than the England average for males and significantly higher than the England average for females.

¹YLL is an estimate of the average years a person would have lived if they had not died prematurely. It is therefore a measure of premature mortality. As a method it is an alternative to death rates that gives more weight to deaths amongst younger people.

Liver disease profile - Blackpool

Alcohol Related Liver Disease

Key Facts

Alcohol is the most common cause of liver disease in England. Alcohol related liver disease accounts for over a third of liver disease deaths. The more someone drinks above the lower-risk guideline, the higher their risk of developing liver disease. The UK is one of the few European countries where alcohol consumption has risen in the last 50 years.

• Between 2010 and 2012, in those under 75 years, an average of 24 men and 6 women died each year in Blackpool from alcohol related liver disease. In 2012/13, there were 74 hospital admissions in Blackpool (42 male and 32 female) where alcoholic liver disease was the primary diagnosis.

• There were 1,097 alcohol specific hospital admissions in Blackpool in 2012/13 (701 male and 396 female). The rate of alcohol specific hospital admissions in Blackpool is significantly higher than the England average for males, and significantly higher than the England average for females.

• There are currently 1,558 premises licensed to serve alcohol in Blackpool. This equates to one licensed premises for every 72 adults. There are 751 premises with 24-hour alcohol licences.

Prevention

The most effective way for an individual to prevent alcohol related liver disease is to drink within the lower-risk guideline. There is strong evidence that opportunistic early identification of people whose health is being damaged by alcohol and brief advice is effective in reducing alcohol consumption and related problems, particularly when delivered in Primary Care and Emergency Departments.

There is good evidence that population level interventions which limit availability and affordability of alcohol through licensing restrictions, minimum pricing and taxation that is proportional to the volume of alcohol are effective in reducing alcohol consumption.

Questions you should ask locally

1. Has alcohol and its links with liver disease been included in your Joint Strategic Needs Assessment (JSNA)?
2. Do you have a local multi-agency alcohol strategy which considers public health and community safety?
3. Are the links between availability of alcohol and alcohol related harm explicitly considered in local licensing policy, and when reviewing new licensing applications?
4. Are local health and social care staff trained to routinely provide early identification of problem drinking and provide brief alcohol advice?
5. Do local alcohol services have sufficient capacity to meet current and future alcohol treatment needs?

Resources

- Health First: An evidence-based alcohol strategy for the UK. <http://www.hf1.ac.uk/resources/management/management/AlcoholStrategy-Updated.pdf>
- Local Alcohol Profiles for England <http://www.lape.org.uk/>
- Longer Lives: <http://www.longerlives.org.uk/>
- National Institute for Health and Care Excellence: Public health guidance Alcohol-use disorders - preventing harmful drinking. <http://www.nice.org.uk/guidance/PH129>
- National Confidential Enquiry into Patient Outcomes and Quality: Alcohol Related Liver Disease: Measuring the Unseen. <http://www.ncepod.com.uk/2013/ALD.pdf>
- The Alcohol Learning Centre <http://www.alcohollearningcentre.org.uk/>



Blackpool key messages YLL

Key messages for Blackpool

In Blackpool, between 2010 and 2012, the average number of years of life lost* in people aged under 75 from liver disease is 89 per 10,000 persons. This compares to 31 for breast cancer, 32 for stroke and 9 for road traffic accidents.

In Blackpool the rate of premature mortality from liver disease between 2010 and 2012, is significantly higher than the England average for males and significantly higher than the England average for females.

Between 2001-03 and 2010-12, the average number of people per year who died with an underlying cause of liver disease in Blackpool, increased from 58 to 64.


The rate of alcohol specific hospital admissions in 2012/13 in Blackpool is significantly higher than the England average for males and significantly higher than the England average for females.

* YLL is an estimate of the average years a person would have lived if they had not died prematurely. It is therefore a measure of premature mortality. As a method it is an alternative to death rates that gives more weight to deaths amongst younger people.



Profile spine charts – Blackpool

N.B. Deprivation, alcohol, hepatitis C





Profile spine charts – Plymouth


Fairly average





Profile spine charts – Southwark


N.B Deprivation, healthcare, Hepatitis B, Obesity (10-11yrs)





Profile spine charts – Cambridgeshire


N.B. Healthcare





Public Health
England

Atlases of Variation




Variations in risk factors, death, admissions and provision of services for Liver Disease – From Liver Disease Atlas

Map 2: Rate of years of life lost in people aged under 75 years due to mortality from chronic liver disease including cirrhosis per population by PCT

Directly standardised rate 2008-2010


Domain 1: Presenting people from dying prematurely
Domain 2: Estimating quality of life for people with long-term conditions




Map 5: Rate of liver cancer mortality in people aged under 75 years per population by PCT



Map 4: Rate of people admitted to hospital at least once for cirrhosis per population by PCT




Map 3: Proportion (%) of admissions attributed to liver disease that are emergency admissions to hospital by PCT




Map 6: Rate of liver transplants from all causes per population by PCT



Map 10: Rate of alcohol-specific admissions in people aged under 19 years per population by PCT




Map 18: Percentage of estimated adult obesity (body mass index ≥30 kg/m²) by PCT



Map 29: Percentage of children in school year 6 classified as overweight or obese by PCT



Map 22: Percentage of hepatitis C test uptake among people who inject drugs receiving drug treatment by PCT




Map 26: Rate of hospital admissions for hepatitis C-related end stage liver disease per population by PCT



Hep C test uptake



HCV admissions

Map H1: Rate of people admitted to hospital at least once for cirrhosis per population, by CCG
 Directly standardised rate, 2014/15



H1: Rate of people admitted to hospital at least once for cirrhosis per population, by CCG


Directly standardised rate, 2014/15





	Example	2005/06	2006/07	2007/08	2008/09	2009/10	2010/11	2011/12	2012/13	2013/14	2014/15	
Max-Min (Range)		190.2	236.3	166.0	164.9	192.8	261.7	218.6	234.8	261.1	271.6	WIDENING Significant
95th-5th percentile		68.5	79.9	79.1	87.0	94.0	108.2	133.2	142.6	141.8	150.5	WIDENING Significant
75th-25th percentile		29.8	33.4	32.6	37.6	37.3	44.6	46.9	46.9	58.9	60.0	WIDENING Significant
Median		54.8	59.6	62.4	64.7	67.1	81.6	86.9	91.7	99.4	108.4	INCREASING Significant

MAP H4P: Rate of alcohol specific admissions for all persons per population, by CCG


Directly standardised rate, 2014/15



H4P: Rate of alcohol specific admissions for all person per population by CCG Directly standardised rate, 2014/15





MAP H4F: Rate of alcohol specific admissions for females per population, by CCG
 Directly standardised rate, 2014/15




H4F: Rate of alcohol specific admissions for females per population by CCG

Directly standardised rate, 2014/15





	Example	2005/06	2006/07	2007/08	2008/09	2009/10	2010/11	2011/12	2012/13	2013/14	2014/15	
Max-Min (Range)		283.1	310.1	461.4	407.7	424.3	487.9	591.8	600.1	571.3	740.1	WIDENING Significant
95th-5th percentile		215.3	250.7	276.9	281.0	289.5	323.0	291.8	279.1	275.3	271.9	No significant change
75th-25th percentile		89.8	97.5	109.4	100.0	167.0	108.6	111.1	102.4	100.9	111.9	WIDENING Significant
Median		100.9	154.0	177.1	181.5	178.0	211.5	220.4	217.4	210.4	215.9	WIDENING Significant

MAP H3: Rate of alcohol specific admissions in people aged under 18 years per population by CCG
 Crude rate per 100,000, 2014/15



H3: Rate of alcohol specific admissions in people aged under 18 years per population by CCG
Crude rate per 100,000, 2014/15



	Example	2005/06	2006/07	2007/08	2008/09	2009/10	2010/11	2011/12	2012/13	2013/14	2014/15	
Max-Min (Range)		224.9	187.8	168.8	154.1	130.3	136.6	114.4	125.5	104.9	103.9	NARROWING Significant
95th-5th percentile		134.2	126.9	110.7	91.0	95.0	86.6	68.7	56.2	57.0	54.9	NARROWING Significant
75th-25th percentile		57.9	57.8	53.8	42.4	40.9	39.8	32.6	24.3	20.2	21.5	NARROWING Significant
Median		69.4	63.8	67.5	55.3	54.1	48.2	43.0	36.2	38.5	34.0	DECREASING Significant



Public Health
England

Protecting and improving the nation's health

Any Questions?

Ask your question on instant messaging
or by email to neolcin@phe.gov.uk



Public Health
England

Protecting and improving the nation's health

Obesity



Public Health
England

HM Government Childhood Obesity A Plan for Action August 2016

PHE-led deliverables

Taking out 20% of sugar in products, achieving salt targets (calories from 2017, & saturated fat considered post SACN)

Updating the nutrient profile model


Supporting early years settings

Harnessing the best new technology


Outcomes

Increase in % children leaving primary school with healthy weight


Reduction in excess weight in adults



Map LD11: Percentage of children in school year 6 classified as overweight or obese by lower-tier local authority 2014/15



LD11: Percentage of children in school year 6 classified as overweight or obese by lower-tier local authority 2014/15





Delivering on the ambition: obesity

- **Tackling the obesogenic environment**
 - Government buying standards for food and catering services (GBSF)
 - Toolkit to improve the food offer “out of home”
- **Systems Wide Prevention Approaches**
 - Support local authorities to deliver a whole systems approach to obesity
- **Supporting healthy eating**
 - Eatwell Guide (March 2016)
 - Change4Life campaign
 - One You campaign
- **Weight Management**
 - Developing weight management toolkits to support commissioners and providers



Public Health
England

Protecting and improving the nation's health

Alcohol



- **The Public Health Burden of Alcohol and the Effectiveness and Cost-Effectiveness of Alcohol Control Policies: An evidence review (2nd December 2016 abridged version in Lancet, full at GOV.UK)**
 - *Reducing the affordability* of alcohol is the most effective and cost effective way of reducing alcohol harm.
 - *Targeting* price increases at the *cheapest alcohol* is very effective and cost-effective and is able to substantially reduce harm in heavy drinkers without affecting moderate drinkers or the price of alcohol sold in pubs and bars.
 - The relationship between *the exposure of children to alcohol marketing* and alcohol consumption is strongly supported by the evidence suggesting that measures to reduce their exposure are important for reducing harm in children
 - *Brief interventions and treatment* are effective in reducing consumption and harm.
 - Providing information and education increases knowledge and awareness, but has little direct impact in reducing harm.



Supporting local planning and delivery


- **Commissioning and planning:**
 - Data products LAPE (Local Alcohol Profiles in England – 19 Indicators)
 - CLearR (model to support local improvement)
- **Licensing**
 - Pilot analytical support package and publish findings
 - Develop and publish analytical support tool
- **Identification and Brief Advice**
 - Have a Word (Wales)
 - STP
 - CQUIN (links % provider income to quality measures, prevention – alcohol/tobacco)





Supporting local planning and delivery

- **Alcohol Services in secondary care**
 - Survey of alcohol care teams (2014, 2016 – most Trusts have provision)
- **Dependent drinkers treatment and recovery**
 - Launching a new commissioning tool and prevalence estimates for alcohol dependence
 - Hosting an alcohol treatment expert group with external stakeholders to inform our programme of work

Map LD13: Percentage of alcohol users that left drug treatment successfully who do not re-present to treatment within 6 months by upper-tier local authority
2015



LD13: Percentage of alcohol users that left drug treatment successfully who do not re-present to treatment within 6 months by upper-tier local authority
2015



Max-Min (Range)		45.8	43.0	43.0	52.5	46.4	49.1	No significant change
95th-5th percentile		29.4	27.7	27.6	23.8	26.7	23.4	No significant change
75th-25th percentile		11.8	12.1	11.6	11.7	11.0	11.3	No significant change
Median		30.7	35.2	35.9	37.0	37.8	38.8	INCREASING Significant



Public Health
England

Resources:

Evidence Review:

<https://www.gov.uk/government/publications/the-public-health-burden-of-alcohol-evidence-review>

[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)32420-5/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32420-5/fulltext)

Data Products:

Local Alcohol Profiles for England (LAPE): <http://www.lape.org.uk/>

National Drugs Treatment Monitoring System: <https://www.ndtms.net/default.aspx>

Support tools

CLearR: <https://www.alcohollearningcentre.org.uk/Topics/Browse/CLearR/>

Have a Word: <https://www.alcohollearningcentre.org.uk/Topics/Browse/have-a-word/>

Alcohol Learning Resource: www.alcohollearningcentre.org.uk



Public Health
England

Protecting and improving the nation's health

Hepatitis B & C



Tackling hepatitis B and C

Action areas

- Prevention of new infections
- Increasing awareness of infection
- Increasing testing and diagnosis
- Getting diagnosed individuals into treatment and care

Progress NHS/PH Outcomes

- ↓ Mortality from liver disease
- ↓ Mortality from causes considered preventable
- ↓ Mortality from cancer
- ↓ Mortality from communicable diseases
- ↑ Successful completion of drug treatment
- ↑ Early diagnosis of cancer
- ↓ Inequalities
- ↑ Quality of life for those with long-term conditions
- ↑ Recovery from ill health
- ↓ Prevention of premature mortality
- ↑ Positive experience of care



PHE hepatitis programme/activity highlights I

- Prevention

Universal hepatitis B infant immunisation programme in 2017

Selective immunisation of at-risk infants-born to hepatitis B infected mothers

- Testing, diagnosis and referral to care

Prisons opt-out testing programme

Feasibility of BBV testing in A&E departments (UCL/PHE NIHR HPRU)

Enhanced management of close contacts of chronic hepatitis B cases

Establishing the **HCV cascade of care** from risk, treatment and outcome through data linkage (UCL/PHE NIHR HPRU)



PHE hepatitis programme/activity highlights II

- **Awareness**

PHE/RCGP co-developed e-training modules:

- course for clinicians: Detection and management of hepatitis B/C
- hepatitis C training course for those who work with drug users:
Enhancing prevention, testing and care

- **Treatment**

Agreeing a national treatment monitoring dataset

Modelling impact of treatment strategies

- **Surveillance for action- publications**

Hepatitis C in UK: 2016 Report

**Shooting Up: Infections among people who inject drugs
in the UK, 2015 -a 2016 update**




Universal infant immunisation programme

- In October 2014 JCVI agreed that universal HBV vaccination of infants in the UK was of considerable public health importance and in line with current global WHO advice
- JCVI recommendation:
*“A universal infant programme using a **hexavalent** infant vaccine (DTaP-IPV-Hib-HBV) should be implemented, subject to procurement at a **cost-effective price**, and such a hexavalent vaccine should be considered the preferred vaccine for use in the UK schedule”*
- Vaccine procured: **planned introduction of universal infant programme in 2017** to replace pentavalent vaccine at 2,3,4 months of age



Selective neonatal immunisation programme

- With universal programme, **still need to maintain and improve selective infant programme**: monovalent birth, 1 month dose plus 12 month dose and testing required
- Since 2012 annual vaccine uptake is >80% for 3 doses by 12 months and >70% for 4 doses by 24 months
- PHE free DBS testing service for at-risk infants at 12 months old launched in 2013
- GP payment for vaccination and testing since 2014






BBV opt-out testing in adult prisons

- National Partnership Agreements between PHE, NHS England and National Offender Management Service in 2013.
- Roll-out since April 2014 informed through phased implementation and evaluation at pathfinder prisons
- Prior to 2010, levels of BBV testing in English prisons **did not exceed 4%** of the prison population
- Formal evaluation shows **an increase in testing across all prisons in England to about 10%** and within **pathfinder prisons** about **20%** of prisoners are currently accepting offer of testing.
- **In England in 2015-16***,
 - 16,425 tests were done for Hepatitis B infection
 - 18, 967 for Hepatitis C infection and
 - (40,705 for HIV infection)
- Full implementation in all adult prisons in England is expected by the **end of FY2016-17**: currently approximately **60% of estate** is implementing the programme.




Mapping cascade of care of hepatitis C

Parameterise models to estimate HCV prevalence and burden of HCV related cirrhosis/ESLD/HCC





Modelling estimates of hepatitis C transmission and burden with the new therapies (PHE & Bristol Uni)



Estimated reduction in **ESLD/HCC** incidence from 1100 in 2015 to 630 in 2020, following the treatment of 3500 cirrhotics per year.

Treating mild-stage PWID was required to make a substantial impact on transmission.

Need two-pronged attack

For clarity, not all transitions are shown, as individuals who achieve SVR but are re-infected then return to their previous state prior to SVR. IFN-R: pegylated interferon and ribavirin; DAA: direct-acting antivirals

Harris et al. J Viral Hep 2016



2016 report: Hepatitis C in the UK

Eliminating hepatitis C as a serious public health threat in the UK

2020 impact targets

Reducing HCV mortality (target 10% reduction by 2020)

Preliminary figures suggest an 11% fall in deaths from Hep C-related end-stage liver disease and cancer in 2015

Reducing new chronic HCV infections (target 30% reduction by 2020)

Surveys of people who inject drugs (PWID) suggest numbers of new HCV infections have remained stable over recent years; both estimated rates of infection and prevalence of infection in recent initiates to drug use were similar in 2015 (8/100 person years and 26% respectively) to those observed in 2011 and 2008

Coverage of key services

Number treated

40% increase in people receiving Hep C treatment in 2015, up from an average of 6,400 in previous years

Proportion of people diagnosed

Only around ½ of PWID sampled in UK surveys were aware of their HCV antibody positive status, and this figure has remained relatively stable over the last five years

Number of sterile needles / syringes provided

Needle/syringe provision was found to be suboptimal, with only around one half of those surveyed reporting adequate provision for their needs



214,000 people estimated to be living with chronic Hep C in the UK





Shooting up: infections among people who inject drugs in the UK, 2015

1 in 200

are living with

hepatitis B

1 in 4

have **not** been **vaccinated**



2 in 5

are living with

hepatitis C



Around half of the
hepatitis C infections
in people who inject
drugs remain
undiagnosed

Of those undiagnosed,


1 in 5

have **never** been **tested**




and **41%** have not been
tested recently


Map LD6: Rate of laboratory reports for confirmed hepatitis C per population by region
 Crude rate per 100,000, 2015



Map LD8: Percentage of hepatitis C test uptake among people who inject drugs receiving drug treatment by upper-tier local authority
 2014/15





Map M4: Rate of mortality from hepatitis C-related end-stage liver disease per population by STP
 Crude rate per 100,000, 2011 - 2015




M4: Rate of mortality from hepatitis C-related end-stage liver disease per population by STP


Crude rate per 100,000, 2011 - 2015



MAP H5: Rate of hospital admissions for hepatitis C - related end stage liver disease or hepatocellular carcinoma per population by STP
 Crude rate per 1,000,000, 2012/13 – 2014/15



Map LD16: Rate of laboratory reports for confirmed hepatitis B per 100,000 population by region
 Crude rate per 100,000, 2015





WHO Global Strategy for Viral Hepatitis

Global Health Sector Strategies for HIV, viral hepatitis, STIs, 2016-2021



Photo collage from GHS consultation meetings

As the world looks to 2030, and prepares to meet the challenges of an ambitious set of Sustainable Development Goals, the World Health Organization developed three global health sector strategies to cover HIV, viral hepatitis, and sexually transmitted infections (STIs). The strategies cover the period 2016-2021 and were endorsed by the Sixty-ninth World Health Assembly on 28 May 2016.

The Sixty-ninth World Health Assembly endorsed the draft strategies





Public Health
England

Protecting and improving the nation's health

Any Questions?

Ask your question on instant messaging
or by email to neolcin@phe.gov.uk



Public Health
England

Protecting and improving the nation's health

Primary Liver Cell Carcinoma

Joint work between UK HCC
Group and NCRAS



Public Health
England

Protecting and improving the nation's health


Primary Liver Cell Carcinoma

Joint work between UK HCC Group and NCRAS

Trends in Liver Cancer Incidence and Mortality

The incidence of Liver Cancer has tripled since the mid 1970s. Incidence and mortality have risen by an average of 4% per year since 1985. This overall figure masks larger annual increases in incidence seen in the mid-1990s.


Figure 6.5: Trends in incidence and mortality of liver cancers by age and sex, England, 1985 to 2011





Source: Best fitting modelled data based on Joinpoint analysis. Underlying data from NCDR, provided by PHE (WM KIT). Joinpoint analysis by Dr Eleanor Curtis and Dr Tom Fowler.

Annual Report of the Chief Medical Officer, Surveillance Volume, 2012: On the State of the Public's Health


Map M3: Rate of liver cancer mortality in people aged under 75 years per population by STP
Directly standardised rate 2011-2015





M3: Rate of liver cancer mortality in people aged under 75 years per population by STP
 Directly standardised rate, 2011-2015



Map H10: Percentage of people aged 15 and over with hepatocellular carcinoma that have had a major liver resection by region
 2010-14




H10: Percentage of people aged 15 and over with hepatocellular carcinoma that have had a major liver resection by region
2010-14



	Example	2010-2014
Max-Min (Range)		4.0
95th-5th percentile		3.1
75th-25th percentile		1.3
Median		7.7


MAP M1u65: Rate of years of life lost in people aged under 65 years due to mortality from chronic liver disease including cirrhosis per population by CCG

Standardised Years of Life Lost per 10,000, 2013-2015





Premature mortality vs. hospital admission for all liver disease





Premature mortality vs. hospital admission for alcohol related liver disease








FIGURE 1.15: BASIC STEPS IN REDUCING THE BURDEN OF LIVER DISEASE



MAP 1.2: LIVER SERVICES AT ACUTE TRUSTS IN ENGLAND SHOWN IN RELATION TO CHRONIC LIVER DISEASE MORTALITY IN MEN PER 100,000 POPULATION BY PCT 2006–2008





Public Health
England


Transplantation

PCT rate of liver transplants (all donors)
4.5 to 28.5 per million population (6-fold variation)

Map 2: Rate of years of life lost in people aged under 75 years due to mortality from chronic liver disease including cirrhosis per population by PCT

Directly standardised rate 2008–2010


Domain 1: Preventing people from dying prematurely
Domain 2: Enhancing quality of life for people with long-term conditions




Map 6: Rate of liver transplants from all donors per population by PCT

2006/07–2010/11

Domain 1: Preventing people from dying prematurely
Domain 2: Enhancing quality of life for people with long-term conditions
Domain 3: Helping people to recover from episodes of ill health or following injury




Source: Right Care Atlas






Oesophageal varices



n : average annual number deaths

Map H9: Percentage of admissions for oesophageal varices that are emergency admissions by CCG
2014/15





Public Health
England

Protecting and improving the nation's health

End of Life Care in Liver Disease

Parallel Planning in Advanced Disease



Liver Disease: silent killer/parallel planning paradox


Admissions to hospital in Last Year of Life

~ 1,000 (1 in 10) people die with

NO admission LYOL

Alcohol related liver disease


- 10% no admissions
- 31% admitted only once
- 26% admitted once and die
- 4% all liver deaths in A&E
- 80% deaths in A&E ARLD



Source : HES-ONS mortality 2007-2011



Opportunities for advanced care planning ?



Source : HES-ONS mortality 2007-2011



Public Health
England

Acknowledgements

Liver Intelligence Service / Atlas of Variation in Liver disease

Liz Rolfe, Tanya Khera-Butler, Sharon Walton

End of Life Care

Ben Hudson, Andy Pring, Brendan Georgeson

Obesity

Alison Tedstone, Margie Van.Dijk

Alcohol

Rosanna O'Connor, Clive Henn

HBV/HCV

Mary Ramsey, Sema Mandal, Monica Desai, Rachel Glass, Maciej Czachorowski,
Eamon O'Moore, Helen Harris



Public Health
England

The Clinical Epidemiology Team





Public Health
England

Protecting and improving the nation's health

Thank you for listening

Any questions?

We will send a survey for your feedback on this webinar.

<https://fingertips.phe.org.uk/profile/atlas-of-variation>

<https://fingertips.phe.org.uk/profile/liver-disease>

neolcin@phe.gov.uk